Updated May 2026
Mounjaro vs Zepbound
Side-by-side comparison of Mounjaro (tirzepatide (T2D injection)) and Zepbound (tirzepatide (injection)) across efficacy, food restrictions, monthly cost, and Medicare Bridge coverage.
Our pick for most patients
Zepbound
Based on the data below, Zepbound wins on covered under the Medicare GLP-1 Bridge ($50/mo from Jul 1, 2026). Your situation may differ — try the personalized matcher on the homepage or compute your real out-of-pocket with the cost calculator on each medication's detail page.
Mounjaro
tirzepatide (T2D injection) · Eli Lilly and Company
No food restriction
Full Mounjaro guide → | Field | Mounjaro | Zepbound |
|---|---|---|
| Route | injection · weekly | injection · weekly |
| Avg weight loss | 12–16% | 18–22% |
| Food restriction | No food restriction | No food restriction |
| Cash from | $1069/mo | $299/mo |
| Savings card | — | — |
| Medicare Bridge | Tier 4 | $50/mo ✓ |
| A1c reduction | −2.4% | — |
| FDA approved | 2022-05 | 2023-11 |
- RouteMounjaroinjection · weeklyZepboundinjection · weekly
- Avg weight lossMounjaro12–16%Zepbound18–22%
- Food restrictionMounjaroNo food restrictionZepboundNo food restriction
- Cash fromMounjaro$1069/moZepbound$299/mo
- Savings cardMounjaro—Zepbound—
- Medicare BridgeMounjaroTier 4Zepbound$50/mo ✓
- A1c reductionMounjaro−2.4%Zepbound—
- FDA approvedMounjaro2022-05Zepbound2023-11
Pick Mounjaro if…
- You can't reliably do a fasting window before meds
Pick Zepbound if…
- You can't reliably do a fasting window before meds
- You're on Medicare and want the $50/mo Bridge price
- Cash pay matters more than peak weight loss ($299/mo cheaper)
- You want the higher peak efficacy (22% vs 16%)
Not sure which fits?
The 30-second matcher on the homepage scores every 2026 GLP-1 against your goals + preferences and recommends the best fit.